Product Details
| Product Name:
PRI-724 |
CAS No.:
1422253-38-0 |
| Purity:
99.11% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | PRI-724 |
| Description | PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction. |
| In vitro | METHODS: CAL27 and FaDu cells were treated with HS-173, erlotinib, and PRI-724 (0-100 μM, 48 hours), and cell viability was analyzed by resazurin assay.
RESULTS The combination of PRI-724 and HS-173 synergistically reduced the viability of FaDu cells; in CAL27 cells, the best inhibitory results were observed with the mixture of PRI-724 and erlotinib. [2] |
| In vivo | METHODS: HCV transgenic mice were treated with PRI-724 (5, 20 mg/kg, intraperitoneally, once a day, for 6 weeks) intraperitoneally, and the antifibrotic activity of PRI-724 against HCV-induced liver fibrosis was evaluated.
RESULTS In HCV transgenic mice, the expression of S100A4, which is controlled by CBP/β-catenin, was increased; this induction was attenuated by the administration of PRI-724, and the HCV-induced increase in hepatic hydroxyproline was also attenuated. Inhibition of CBP/β-catenin by PRI-724 is effective against HCV-induced liver fibrosis. [1]
METHODS: HCV transgenic mice were treated with PRI-724 (0.1, 0.3, 1 mg/kg, subcutaneous injection, 6 weeks) to evaluate the anti-fibrotic activity of PRI-724.
RESULTS PRI-724 can effectively reduce the area of ??collagen fibers in the liver in a dose-dependent manner and increase the expression level of Mmp8 mRNA and the number of F4/80, Ly-6C and Gr-1 positive cells. [1] |
| Storage | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (83.51 mM)
Ethanol : 1.8 mg/mL (2.7 mM)
|
| Keywords | PRI724 | PRI-724 | PRI 724 |
| Inhibitors Related | Urea | Wnt pathway activator 1 | L-quebrachitol | MSAB | EMT inhibitor-1 | Wogonin | CHIR-99021 | XAV-939 | (E)-Ferulic acid | Nefopam hydrochloride | KY-05009 | Bisdemethoxycurcumin |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:70006-24-5
$270.00 / 50mg
-
CAS:587870-77-7
$34.00 / 5mg
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States